Inventor · disambiguated record
Shripad S. Bhagwat
Also filed as: BHAGWAT SHRIPAD · BHAGWAT SHRIPAD S · BHAGWAT SHRIPAD SUBRAY
43 granted patents·14 pending applications·966 citations·filing 1985–2023
98Inventor score
Files withSIGNAL PHARM LLC11AMBIT BIOSCIENCES CORP8SIGNAL PHARM INC8CIBA GEIGY CORP5BHAGWAT SHRIPAD S4
Top patents by PatentIndex Score
57 records- 0196US5665721AHeterocyclic substituted cyclopentane compoundsABBOTT LAB·Filed 1995·Granted Sep 9, 1997·113 cites·32 claims
- 0295US5670497ACyclic hydrazine compoundsCIBA GEIGY CORP·Filed 1994·Granted Sep 23, 1997·66 cites·17 claims
- 0393US8129374B2Method of using imidazolothiazole compounds for the treatment of diseaseBHAGWAT SHRIPAD·Filed 2010·Granted Mar 6, 2012·34 cites·42 claims
- 0493US7129242B2Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related theretoSIGNAL PHARM LLC·Filed 2001·Granted Oct 31, 2006·59 cites·2 claims
- 0593US6897231B2Indazole derivatives as JNK inhibitors and compositions and methods related theretoSIGNAL PHARM INC·Filed 2001·Granted May 24, 2005·62 cites·26 claims
- 0692US5807891AAntiviral ethers of aspartate protease substrate isosteresCIBA GEIGY AG·Filed 1997·Granted Sep 15, 1998·54 cites·13 claims
- 0791US6331562B1Compounds and methods for modulation of estrogen receptorsSIGNAL PHARM INC·Filed 2000·Granted Dec 18, 2001·63 cites·63 claims
- 0891US6291456B1Compounds and methods for modulation of estrogen receptorsSIGNAL PHARM INC·Filed 2000·Granted Sep 18, 2001·62 cites·78 claims
- 0990US8618289B2RAF kinase modulator compounds and methods of use thereofABRAHAM SUNNY·Filed 2009·Granted Dec 31, 2013·22 cites·26 claims
- 1090US7820657B2Imidazolothiazole compounds for the treatment of diseaseAMBIT BIOSCIENCES CORP·Filed 2007·Granted Oct 26, 2010·13 cites·37 claims
- 1189US9320739B2RAF kinase modulator compounds and methods of use thereofAMBIT BIOSCIENCES CORP·Filed 2015·Granted Apr 26, 2016·6 cites·11 claims
- 1289US5753652AAntiretroviral hydrazine derivativesNOVARTIS AG·Filed 1995·Granted May 19, 1998·49 cites·18 claims
- 1388US8969587B2RAF kinase modulator compounds and methods of use thereofAMBIT BIOSCIENCES CORP·Filed 2013·Granted Mar 3, 2015·8 cites·14 claims
- 1488US6593322B1Compounds and methods for modulation of estrogen receptorsSIGNAL PHARM INC·Filed 2000·Granted Jul 15, 2003·31 cites·26 claims
- 1587US6436923B1Compounds and methods for modulation of estrogen receptorsSIGNAL PHARM INC·Filed 2000·Granted Aug 20, 2002·26 cites·50 claims
- 1686US7442699B2Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related theretoSIGNAL PHARM LLC·Filed 2005·Granted Oct 28, 2008·10 cites·8 claims
- 1786US7220771B2Methods of using indazole derivatives as JNK inhibitorsSIGNAL PHARM LLC·Filed 2003·Granted May 22, 2007·22 cites·4 claims
- 1886US6620838B1Benzopyrazone compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM INC·Filed 2002·Granted Sep 16, 2003·24 cites·33 claims
- 1985US5663200AAntiviral ethers of aspartate protease substrate isosteresCIBA GEIGY CORP·Filed 1995·Granted Sep 2, 1997·28 cites·11 claims
- 2083US7211594B2Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewithSIGNAL PHARM LLC·Filed 2003·Granted May 1, 2007·23 cites·6 claims
- 2183US7208513B2Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewithSIGNAL PHARM LLC·Filed 2004·Granted Apr 24, 2007·16 cites·12 claims
- 2283US7122544B2Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related theretoSIGNAL PHARM LLC·Filed 2001·Granted Oct 17, 2006·20 cites·20 claims
- 2382US7119114B1Pyrazoloanthrone and derivatives thereof as JNK inhibitors and compositions and methods related theretoSIGNAL PHARM LLC·Filed 2000·Granted Oct 10, 2006·16 cites·19 claims
- 2482US6686351B2Compounds and methods for modulation of estrogen receptorsSIGNAL PHARM INC·Filed 2002·Granted Feb 3, 2004·15 cites·18 claims
- 2580US6372739B1Compounds and methods for modulation of estrogen receptorsSIGNAL PHARM INC·Filed 2001·Granted Apr 16, 2002·13 cites·20 claims
- 2679US7429599B2Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNKSIGNAL PHARM LLC·Filed 2003·Granted Sep 30, 2008·12 cites·4 claims
- 2779US5935976AAntiviral ethers of aspartate protease substrate isosteresNOVARTIS AG·Filed 1998·Granted Aug 10, 1999·18 cites·10 claims
- 2878US10053430B2RAF kinase modulator compounds and methods of use thereofAMBIT BIOSCIENCES CORP·Filed 2017·Granted Aug 21, 2018·1 cites·2 claims
- 2975US9730937B2RAF kinase modulator compounds and methods of use thereofAMBIT BIOSCIENCES CORP·Filed 2016·Granted Aug 15, 2017·1 cites·19 claims
- 3072US7247646B2Benzopyranone compounds, compositions thereof, and methods of treatment therewithNOVARTIS AG·Filed 2004·Granted Jul 24, 2007·6 cites·4 claims
- 3171US9585892B2Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewithAMBIT BIOSCIENCES CORP·Filed 2014·Granted Mar 7, 2017·1 cites·20 claims
- 3270US8557810B2Imidazolothiazole compounds for the treatment of diseaseBHAGWAT SHRIPAD·Filed 2012·Granted Oct 15, 2013·1 cites·22 claims
- 3370US5025025A(Arylsulfonamido- and pyridyl-)-substituted carboxylic acids and derivatives thereof and use for suppressing thromboxane activityCIBA GEIGY CORP·Filed 1990·Granted Jun 18, 1991·12 cites·60 claims
- 3469US8883783B2Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewithBHAGWAT SHRIPAD S·Filed 2008·Granted Nov 11, 2014·2 cites·23 claims
- 3569US6030969A5,6,7-trisubstituted-4-aminopyrido[2,3-D] pyrimidine compoundsABBOTT LAB·Filed 1998·Granted Feb 29, 2000·14 cites·16 claims
- 3664US2015126505A1Imidazolothiazole compounds for the treatment of diseaseAMBIT BIOSCIENCES CORP·Filed 2014·Application pending·0 cites
- 3763US2023416741A1Method of treating duchenne muscular dystrophyBIOMARIN PHARM INC·Filed 2023·Application pending·0 cites
- 3861US6143749AHeterocyclic substituted cyclopentane compoundsABBOTT LAB·Filed 1996·Granted Nov 7, 2000·17 cites·20 claims
- 3961US2017348320A1Imidazolothiazole compounds for the treatment of diseaseAMBIT BIOSCIENCES CORP·Filed 2017·Application pending·0 cites
- 4059US5643878A5-amino-4-hydroxyhexanoic acid derivativesCIBA GEIGY CORP·Filed 1994·Granted Jul 1, 1997·25 cites·25 claims
- 4158US2007060616A1Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compoundsSIGNAL PHARM LLC·Filed 2006·Application pending·0 cites
- 4253US7335676B2Methods for treating inflammatory conditions or inhibiting JNKSIGNAL PHARM LLC·Filed 2003·Granted Feb 26, 2008·0 cites·6 claims
- 4353US7279489B2Compounds and methods for modulation of estrogen receptorsSIGNAL PHARM LLC·Filed 2003·Granted Oct 9, 2007·0 cites·7 claims
- 4453US2009099178A1Indazole compounds and methods of use thereofBHAGWAT SHRIPAD S·Filed 2008·Application pending·0 cites
- 4552US2024254098A1Thioester prodrugs for the treatment of renal anomaliesALTIBIO INC·Filed 2022·Application pending·0 cites
- 4648US2004092572A1Benzopyranone compounds, compositions thereof, and methods of treatment therewithFiled 2003·Application pending·0 cites
- 4748US2006004043A1Indazole compounds and methods of use thereofBHAGWAT SHRIPAD S·Filed 2004·Application pending·0 cites
- 4848US2005009876A1Indazole compounds, compositions thereof and methods of treatment therewithFiled 2003·Application pending·0 cites
- 4946US2004072888A1Methods for treating inflammatory conditions or inhibiting JNKFiled 2003·Application pending·0 cites
- 5044US2007015817A14-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewithMCKIE JEFFREY A·Filed 2006·Application pending·0 cites
Showing the top 50 of 57 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →